Oral bisphosphonates and osteonecrosis of the jaw: are the MHRA recommendations appropriate?
Compston
Juliet
J
D050071:Bone Density Conservation Agents / Q000008:administration & dosage / Q000009:adverse effects*; D004164:Diphosphonates / Q000008:administration & dosage / Q000009:adverse effects*; D005260:Female; D006801:Humans; D007571:Jaw Diseases / Q000139:chemically induced* / Q000517:prevention & control; D010020:Osteonecrosis / Q000139:chemically induced* / Q000517:prevention & control; D015663:Osteoporosis, Postmenopausal / Q000188:drug therapy; D017410:Practice Guidelines as Topic; D006113:United Kingdom; D016387:Women's Health
D050071:Bone Density Conservation Agents; D004164:Diphosphonates